Sector
PharmaceuticalsOpen
₹627.9Prev. Close
₹624.65Turnover(Lac.)
₹1,283.44Day's High
₹642.8Day's Low
₹618.9552 Week's High
₹74552 Week's Low
₹263.3Book Value
₹139.75Face Value
₹5Mkt Cap (₹ Cr.)
1,965.43P/E
45.17EPS
13.82Divi. Yield
0.14Here are some of the stocks that may see significant price movement today: BHEL, IRCTC, Birlasoft, Bajaj Healthcare, etc.
Earlier this year, Bajaj Healthcare secured formal CMO agreements with customers in the United Kingdom and the European Union to deliver 15 APIs.
The strategic partnership aims to enhance Bajaj Healthcare's presence in the European pharmaceutical market.
Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 13.8 | 13.8 | 13.8 | 13.8 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 264.56 | 353.89 | 314.69 | 244.61 |
Net Worth | 278.36 | 367.69 | 328.49 | 258.41 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
---|---|---|---|---|
Revenue | 656.98 | 410 | 370.17 | 327.1 |
yoy growth (%) | 60.23 | 10.76 | 13.16 | 41.81 |
Raw materials | -377.89 | -263.23 | -242.02 | -215.28 |
As % of sales | 57.51 | 64.2 | 65.38 | 65.81 |
Employee costs | -34.54 | -28.43 | -24.61 | -21.65 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
---|---|---|---|---|
Profit before tax | 118.81 | 32.45 | 24.16 | 22.68 |
Depreciation | -16.12 | -12.12 | -11.41 | -11.08 |
Tax paid | -35.71 | -9.95 | -7.85 | -7.49 |
Working capital | 78.78 | 14.98 | 9.66 | 26.86 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 60.23 | 10.76 | 13.16 | 41.81 |
Op profit growth | 184.93 | 12.24 | 8.66 | 27.97 |
EBIT growth | 226.77 | 20.85 | 6.55 | 39.23 |
Net profit growth | 269.37 | 37.94 | 7.4 | 94.08 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,788.8 | 136.25 | 4,29,217.03 | 1,181.05 | 0.75 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,924.5 | 75.78 | 1,57,100.32 | 594 | 0.51 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,533.7 | 26.61 | 1,23,852.12 | 1,438.15 | 0.85 | 4,134.87 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,332.4 | 61.86 | 1,12,844.49 | 485 | 0.84 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,545.5 | 54.3 | 1,05,003.3 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
Sanjankumar R Bajaj
Managing Director
Anil C Jain
Whole-time Director
Namrata S Bajaj
Whole-time Director
Dhananjay S Halte
Independent Director
Ram B Banarase
Independent Director
Hemant R Karnik
Independent Director
Loukik D Tipnis
Independent Director
Kejal Shah
Whole-time Director
Pakshal Jain
Company Sec. & Compli. Officer
MONICA TANWAR
Independent Director
Sandeep Shah
Independent Director
Yaqoob Ali
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Bajaj Healthcare Ltd
Summary
Bajaj Healthcare Ltd. is a bulk drug manufacturer established in 1993, serving various Pharmaceuticals, Nutraceuticals and Food industries globally with a spirit of scrupulousness. The Company commenced its operations in 1993 with a single unit at Tarapur. It became a public company in 2005 and listed its shares in the Indian stock exchanges in 2016. With Headquartered in Thane, Company has established 3 API plants in Gujarat and Maharashtra. It has 4 units for APIs/ intermediates and one unit for formulation, which are designed to meet the requirements of both advanced as well as emerging market opportunities. In 2008, the Company acquired Formulations plant at Manjusar, Vadodara and have converted it into WHO-GMP compliant facility. In 2013, it set up another API and Intermediate manufacturing plant at Panoli, Ankleshwar and acquired and set up an Intermediate Unit in Tarapur MIDC, near Mumbai in November, 2014.In FY 2019-20, the Company acquired Intermediates manufacturing Unit at MIDC, Tarapur Maharashtra and also agreed to acquire Four Manufacturing facilities, comprising of three APIs manufacturing facilities, one Engineering Unit, at MIDC Tarapur, Maharashtra along with an Industrial Plot at Dahej, Gujarat.The Company started commercial operations at Panoli Unit, in Bharuch from May 11, 2022. In 2021-22, it launched a Nutraceutical named Magnesium L-Threonate; commenced commercial production at Tarapur, for Nimesulide API, used for relief from pain and prevention of fe
Read More
The Bajaj Healthcare Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹622.3 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Bajaj Healthcare Ltd is ₹1965.43 Cr. as of 24 Apr ‘25
The PE and PB ratios of Bajaj Healthcare Ltd is 45.17 and 4.42 as of 24 Apr ‘25
The 52-week high/low is the highest and lowest price at which a Bajaj Healthcare Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Bajaj Healthcare Ltd is ₹263.3 and ₹745 as of 24 Apr ‘25
Bajaj Healthcare Ltd's CAGR for 5 Years at 11.47%, 3 Years at 22.88%, 1 Year at 95.91%, 6 Month at 72.01%, 3 Month at 6.21% and 1 Month at -9.54%.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.